研究显示,新哮喘药物Tezepelumab 显著地减少了鼻腔聚虫和相关症状。 New asthma drug Tezepelumab dramatically reduces nasal polyps and related symptoms, study shows.

临床试验显示,Tezepelumab是一种哮喘药物,可大大降低鼻腔聚氨酯的强度,并可改善鼻腔堵塞和嗅觉等症状。 A clinical trial shows that Tezepelumab, an asthma drug, significantly reduces nasal polyp severity and improves symptoms like nasal congestion and sense of smell. 与安慰剂相比,该药物还分别减少了对外科手术和园艺类固醇的需求近98%和88%。 The drug also reduced the need for surgery and corticosteroids by nearly 98% and 88%, respectively, compared to a placebo. 这些结果发表在《新英格兰医学杂志》上,表明该药物可以大大减轻病人鼻腔膜结膜片的负担。 These results, published in the New England Journal of Medicine, suggest the drug could greatly ease the burden of nasal polyps for patients.